Ultragenyx Pharmaceutical Inc
RARE24.700USD
+0.910+3.83%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
2.38B시가총액
손실P/E TTM
자세한 내용은 Ultragenyx Pharmaceutical Inc 회사
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Ultragenyx Pharmaceutical Inc 정보
종목 코드 RARE
회사 이름Ultragenyx Pharmaceutical Inc
상장일Jan 31, 2014
CEOKakkis (Emil D)
직원 수1294
유형Ordinary Share
회계 연도 종료Jan 31
주소60 Leveroni Ct
도시NOVATO
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호94949
전화14154838800
웹사이트https://www.ultragenyx.com/
종목 코드 RARE
상장일Jan 31, 2014
CEOKakkis (Emil D)
Ultragenyx Pharmaceutical Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-31783.00%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+31589.00%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+19104.00%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+5740.00%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+5740.00%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+5740.00%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Independent Director
Independent Director
18.02K
+5740.00%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
1.52K
-3150.00%
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. John R. Pinion, II
Mr. John R. Pinion, II
Chief Quality Officer, Executive Vice President - Translational Sciences
Chief Quality Officer, Executive Vice President - Translational Sciences
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-31783.00%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+31589.00%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+19104.00%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+5740.00%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+5740.00%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+5740.00%
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
사업별USD
이름
수익
비율
Crysvita royalty revenue
64.94M
40.60%
Crysvita
47.00M
29.39%
Dojolvi
24.27M
15.18%
Evkeeza
16.72M
10.45%
Mepsevii
7.00M
4.38%
지역별USD
이름
수익
비율
North America
83.54M
52.23%
Latin America
43.36M
27.11%
Europe
27.88M
17.43%
Asia Pacific
5.15M
3.22%
사업별
지역별
사업별USD
이름
수익
비율
Crysvita royalty revenue
64.94M
40.60%
Crysvita
47.00M
29.39%
Dojolvi
24.27M
15.18%
Evkeeza
16.72M
10.45%
Mepsevii
7.00M
4.38%
주식 보유 통계
마지막 업데이트: Sat, Feb 7
마지막 업데이트: Sat, Feb 7
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
10.62%
BlackRock Institutional Trust Company, N.A.
5.26%
Fidelity Management & Research Company LLC
4.07%
Sands Capital Management, LLC
3.91%
State Street Investment Management (US)
3.83%
기타
72.32%
주주
주주
비율
The Vanguard Group, Inc.
10.62%
BlackRock Institutional Trust Company, N.A.
5.26%
Fidelity Management & Research Company LLC
4.07%
Sands Capital Management, LLC
3.91%
State Street Investment Management (US)
3.83%
기타
72.32%
주주 유형
주주
비율
Investment Advisor
52.00%
Investment Advisor/Hedge Fund
31.58%
Hedge Fund
14.45%
Individual Investor
3.48%
Research Firm
2.31%
Sovereign Wealth Fund
1.02%
Private Equity
1.02%
Pension Fund
0.82%
Bank and Trust
0.43%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
665
100.29M
103.96%
-2.21M
2025Q3
640
97.34M
100.90%
-3.53M
2025Q2
635
97.48M
101.32%
-2.63M
2025Q1
652
96.83M
102.45%
-3.19M
2024Q4
645
94.29M
102.32%
-4.54M
2024Q3
633
93.51M
101.49%
-6.93M
2024Q2
618
95.17M
101.90%
+3.05M
2024Q1
605
86.17M
101.67%
-4.74M
2023Q4
588
86.44M
105.27%
+5.64M
2023Q3
574
75.90M
106.07%
-3.60M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
10.11M
10.48%
-80.69K
-0.79%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.07M
5.26%
+54.55K
+1.09%
Sep 30, 2025
Fidelity Management & Research Company LLC
3.92M
4.07%
+1.65M
+72.84%
Sep 30, 2025
Sands Capital Management, LLC
3.77M
3.91%
-173.63K
-4.40%
Sep 30, 2025
State Street Investment Management (US)
3.69M
3.83%
+1.12M
+43.55%
Sep 30, 2025
RTW Investments L.P.
3.26M
3.38%
+1.55M
+90.83%
Sep 30, 2025
JP Morgan Asset Management
3.25M
3.37%
+644.31K
+24.74%
Sep 30, 2025
Fidelity Institutional Asset Management
3.36M
3.48%
+3.02M
+906.25%
Sep 30, 2025
Baker Bros. Advisors LP
2.77M
2.87%
--
--
Sep 30, 2025
Kakkis (Emil D)
2.69M
2.79%
-31.78K
-1.17%
Mar 07, 2025
더 보기
관련 ETF
마지막 업데이트: Tue, Dec 2
마지막 업데이트: Tue, Dec 2
이름
비율
Motley Fool Small-Cap Growth ETF
3.73%
Global X Genomics & Biotechnology ETF
3.19%
Franklin Genomic Advancements ETF
1.59%
Virtus LifeSci Biotech Products ETF
1.41%
State Street SPDR S&P Biotech ETF
1.32%
WisdomTree BioRevolution Fund
0.94%
Direxion Daily S&P Biotech Bull 3X Shares
0.81%
Touchstone Sands Capital US Select Growth ETF
0.8%
Goldman Sachs Future Health Care Equity ETF
0.6%
First Trust Multi-Manager Large Growth ETF
0.54%
더 보기
Motley Fool Small-Cap Growth ETF
비율3.73%
Global X Genomics & Biotechnology ETF
비율3.19%
Franklin Genomic Advancements ETF
비율1.59%
Virtus LifeSci Biotech Products ETF
비율1.41%
State Street SPDR S&P Biotech ETF
비율1.32%
WisdomTree BioRevolution Fund
비율0.94%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.81%
Touchstone Sands Capital US Select Growth ETF
비율0.8%
Goldman Sachs Future Health Care Equity ETF
비율0.6%
First Trust Multi-Manager Large Growth ETF
비율0.54%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
